Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$195.31 USD

195.31
1,866,244

-1.51 (-0.77%)

Updated Oct 3, 2024 02:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square

The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square

Top Ranked Income Stocks to Buy for October 2nd

Here are three stocks with buy rank and strong income characteristics for investors to consider today, October 2nd.

Mark Vickery headshot

Top Stock Reports for AbbVie, Starbucks & Phillips 66

Today's Research Daily features new research reports on 12 major stocks, including AbbVie (ABBV), Starbucks (SBUX) and Phillips 66 (PSX).

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

AbbVie (ABBV) closed at $75.73 in the latest trading session, marking a +1.18% move from the prior day.

Is AbbVie (ABBV) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know

AbbVie (ABBV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here is Why Growth Investors Should Buy AbbVie (ABBV) Now

AbbVie (ABBV) could produce exceptional returns because of its solid growth attributes.

AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug

AbbVie (ABBV) gets FDA approval for the label expansion of Mavyret.

This is Why AbbVie (ABBV) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

AbbVie (ABBV) closed at $72.97 in the latest trading session, marking a +0.8% move from the prior day.

AC Immune to Earn Milestone From Lilly for Alzheimer's Drug

AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.

The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK

The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK

Mark Vickery headshot

Top Analyst Reports for AbbVie, Union Pacific & CSX

Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Union Pacific (UNP) and CSX (CSX).

Novartis Announces New Data on Spondylitis Drug Cosentyx

Novartis (NVS) announces new positive data from a phase III study on Cosentyx in patients with active nr-axSpA.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $70.59, moving +0.11% from the previous trading session.

Neena Mishra headshot

Dividend Growth ETFs for Long Term Investors

Dividend growth ETFs hold companies with solid balance sheets and rising earnings.

Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland

Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.

Kinjel Shah headshot

4 Big Drugmakers Boasting Impressive Oncology Pipelines

We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.

Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $66.70, moving -1.36% from the previous trading session.

The Zacks Analyst Blog Highlights: Microsoft, Home Depot, AbbVie, Disney and Host Hotels

The Zacks Analyst Blog Highlights: Microsoft, Home Depot, AbbVie, Disney and Host Hotels

Mark Vickery headshot

Top Stock Reports for Microsoft, Home Depot & AbbVie

Today's Research Daily features updated research reports on 16 major stocks, including Microsoft (MSFT), Home Depot (HD) and AbbVie (ABBV).

J&J's Stelara Gets Approval in EU for Ulcerative Colitis

Johnson & Johnson (JNJ) receives European Commission's (EC) approval for the label expansion of Stelara for the treatment of adults with moderately-to-severely active ulcerative colitis (UC).

The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie

The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie

AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails

IDMC recommends termination of AbbVie's (ABBV) late-stage study on its small cell lung cancer candidate, Rova-T. AbbVie discontinues development.